METHODS FOR TREATING MUSCULAR DYSTROPHY USING THE SAME

Kaplanet al. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release. Jan. 20, 2005: 102(1):247 53. * Sonnemann et al. Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLOS Med. May 26, 2009;6(5): e1000083. * Lai et al O2 and C3 helices of dystrophin R16 and R17 frame a microdomain in the Oil helix of dystrophin R17 for neuronal NOS binding. PNAS. 2013; 110 (2): 525-530. * Adams ME, et al. (2000) Absence of alpha-syntrophin leads to structurally aberrant neuromuscular synapses deficient in utrophin. J Cell Biol 150(6): 1385-1398. Betts, C. A. , Hammond, S. M. , Yin, H. F. & Wood, M. J. Optimizing tissue-specific antisense oligonucleotide-Peptide conjugates. Meth ods Mol Biol 867, 415-435 (2012). Bhagavati, S. Exon-skipping therapy for Duchenne muscular dys trophy. Lancet 379, e10; author reply e10-11 (2012). Bostick, B. , Ghosh, A. , Yue, Y. Long, C. & Duan, D. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther 14, 1605-1609 (2007). Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS (1995) Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82(5):743-752. Brenman, J. E. et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin medi ated by PDZ domains. Cell 84, 757-767 (1996). Chao DS, et al. (1996) Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 184 (2):609 618. Choy, E. et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell 98, 69-80 (1999). Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, doseescalation study. Lancet 378, 595-605 (2011). Dinovic-Carugo K. Gautel M. Ylänne J. Young P (2002) The spectrin repeat: A structural platform for cytoskeletal protein assem blies. FEBS Lett 513(1): 119-123. England, S. B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182 (1990). Foster, H. et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther 16, 1825-1832 (2008). Goemans, N. M. et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364, 1513-1522 (2011). Grady RM, et al. (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 90(4):729-738. Gregorevic, P. et al. raAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12, 787-789 (2006). Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adenoassociated viral vectors. Nat Med 10, 828-834 (2004). Hancock JF, Paterson H. Marshall CJ (1990) A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63(1):133-139. (Continued)